Policy Sclerosis Is Ravaging the NHS and Whitehall

Why It Matters

It highlights that drug‑centric strategies are failing to improve population health, signalling a need for policy reform that prioritises prevention and socioeconomic security.

Key Takeaways

• UK healthy life expectancy fell to 61 years, 20th globally
• Myocardial infarction rates stalled after 2010 despite 80M statin prescriptions
• Smoking and salt reduction cut heart disease risk faster than drugs
• Public health taxation and education outperform pharmaceutical interventions for population health

Pulse Analysis

The Health Foundation’s latest analysis places the United Kingdom in a starkly unfavorable position on healthy life expectancy (HLE), a metric that gauges the years an individual can expect to live in good health. While most high‑income peers have recorded modest gains, the UK’s HLE has slipped by roughly two years over the past decade, landing just under 61 years and ranking 20th out of 21. This regression underscores a broader systemic issue: the nation’s health policies have drifted away from proven preventive strategies toward a reliance on medical treatment alone.

At the heart of the report is the concept of "myopic policy sclerosis" (MPS), a term coined to describe the entrenched belief that disease prevention hinges on pharmaceuticals rather than public‑health interventions. The data on myocardial infarction (MI) illustrate this point vividly. After a steady decline driven by reduced smoking rates and a national salt‑reduction programme, MI incidence plateaued around 2010 despite an explosion in drug prescriptions—80 million statin scripts and four times that number for antihypertensives each year. The resurgence of heart attacks signals that medication alone cannot offset the growing burden of obesity, type‑2 diabetes, and other metabolic disorders.

The report calls for a decisive policy pivot: re‑embrace taxation, regulation, and health education that proved effective in the 1970s and 2000s. Reinstating robust tobacco taxes, expanding salt‑reduction mandates, and ensuring affordable, nutritious food options could deliver health gains far beyond what an "ocean of pharmaceuticals" can achieve. Moreover, integrating health considerations across all government departments—an approach championed by Labour’s shadow health secretary—could address the socioeconomic determinants of ill health. By moving from a drug‑first mindset to a prevention‑first framework, the UK can halt the HLE decline and restore its population’s wellbeing.